# Apyx Medical Corporation Announces Retrospective Clinical Publication Evaluating Clinical Benefit of Renuvion® Used in Combination with Liposuction Canonical URL: https://biopharmsignal.com/news/APYX/apyx-medical-corporation-announces-retrospective-clinical-publication-evaluating-065196d3 Ticker: APYX Company: Apyx Medical Source: Apyx Medical Published: 2026-05-14 12:00 EST ## Summary Analysis showed that liposuction followed by helium plasma RF was associated with higher patient-reported satisfaction with abdominal appearance, lower... ## Article Body Analysis showed that liposuction followed by helium plasma RF was associated with higher patient-reported satisfaction with abdominal appearance, lower abdominoplasty and revision rates, and comparable complication rates versus conventional liposuction alone May 14, 2026 08:00 ET | Source: Apyx Medical Corporation CLEARWATER, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion ® and the AYON Body Contouring System™ (AYON), today announced the publication of a new retrospective investigator-initiated study in Plastic and Reconstructive Surgery - Global Open 1 . The study evaluated patient-reported outcomes following liposuction with and without helium plasma radiofrequency (Renuvion). The results demonstrate that adding Renuvion to liposuction resulted in statistically significant improvements in patient-reported satisfaction with abdominal appearance and excess skin, along with lower rates of abdominoplasty and surgical revisions, while maintaining comparable complication rates to power-assisted liposuction. Key Findings from the 113‑Patient Study Patients treated with Renuvion reported statistically higher satisfaction with reduced appearance of excess skin (Body‑Q score 87.8 vs. 73.8; p=0.03) Among patients who did not undergo abdominoplasty, satisfaction with abdominal appearance was also statistically higher (68.8 vs. 45.0; p=0.039) The rate of patients requiring abdominoplasty was more than 50% lower in the Renuvion group compared to the group receiving power-assisted liposuction only (30.0% vs. 67.1%) Revision rates were significantly lower in the Renuvion group (12.0% vs. 37.5%; p=0.038) Complication rates remained similar between groups (2.5% vs. 2.7%) “This study adds to the growing body of clinical evidence supporting the use of Renuvion in aesthetic body contouring,” said Charlie Goodwin, President and Chief Executive Officer of Apyx Medical. “With more than 2 million liposuction procedures performed globally each year*, these statistically significant improvements in patient satisfaction and reduced revision rates underscore the value Renuvion provides to aesthetic surgeons and their patients.” The retrospective study, led by Pablo D. Huber, MD, evaluated long-term (>12 month) Body-Q® patient-reported outcomes, procedural data, and safety profiles across 113 patients treated by a single surgeon. The Renuvion cohort (power-assisted liposuction + Renuvion) consistently reported higher satisfaction with skin quality and abdominal contour, with no increase in complications. Apyx Medical’s latest technology, the AYON Body Contouring System™, builds on the proven foundation and technology of Renuvion, leveraging decades of clinical evidence and real-world experience to deliver precise, efficient, and effective energy-based solutions in an all-in-one system. 1 A digital version of the clinical publication is available via the following link: Plastic and Reconstructive Surgery – Global Open. *Source: ISAPs 2024 Survey About AYON Body Contouring System™: AYON is a groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates advanced fat removal technologies, Renuvion’s tissue contraction and electrosurgical capabilities, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. With advanced features like LIFT Technology for real-time adjustments and Renuvion for enhanced tissue contraction, AYON sets a new standard in surgical care, streamlining procedures and maximizing patient outcomes. Backed by Apyx Medical’s expertise and evidence-based design, AYON delivers consistent, reliable performance and an unmatched return on investment. As the first of its kind, AYON is revolutionizing body contouring and shaping the future of aesthetic surgery. Apyx Medical Corporation : Apyx Medical Corporation is a surgical aesthetics company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion and the AYON Body Contouring System™ in the cosmetic surgery market and J-Plasma ® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The AYON Body Contouring System is an FDA-cleared, groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates fat removal, closed loop contouring, electrosurgical capabilities and Renuvion for tissue contraction, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com . Investor Relations Contact: Jeremy Feffer Managing Director LifeSci Advisors OP: 212-915-2568 jfeffer@lifesciadvisors.com ## Recent Company News - 2026-07-28 12:00 EST — [Apyx Medical Corporation to Participate in the Canaccord Genuity 46th Annual Growth Conference](https://biopharmsignal.com/news/APYX/apyx-medical-corporation-to-participate-in-the-canaccord-genuity-46th-annual-gro-94590452) — Source: Apyx Medical - 2026-07-23 12:00 EST — [Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026](https://biopharmsignal.com/news/APYX/apyx-medical-corporation-to-release-second-quarter-of-fiscal-year-2026-financial-0275b558) — Source: Apyx Medical - 2026-05-21 12:00 EST — [New Study Shows Significant Improvement in Cellulite and Skin Laxity with Advanced Minimally Invasive Treatment Utilizing Avéli® and Renuvion®](https://biopharmsignal.com/news/APYX/new-study-shows-significant-improvement-in-cellulite-and-skin-laxity-with-advanc-d19ed0bc) — Source: Apyx Medical - 2026-05-14 12:00 EST — [Apyx Medical Corporation Announces Retrospective Clinical Publication Evaluating Clinical Benefit of Renuvion® Used in Combination with Liposuction](https://biopharmsignal.com/news/APYX/apyx-medical-corporation-announces-retrospective-clinical-publication-evaluating-065196d3) — Source: Apyx Medical - 2026-05-11 12:00 EST — [Apyx Medical Corporation Receives Expanded FDA 510(k) Clearance Adding Power Liposuction Capability to AYON Body Contouring System™](https://biopharmsignal.com/news/APYX/apyx-medical-corporation-receives-expanded-fda-510-k-clearance-adding-power-lipo-c64ec7c1) — Source: Apyx Medical ## Related News - 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627) - 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922) - 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c) - 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec) - 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)